• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immuneering Corporation - Class A Common Stock (NQ:IMRX)

    4.400 -0.030 (-0.68%)
    Streaming Delayed Price Updated: 9:31 AM EST, Jan 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 101,779
    Open 4.460
    Bid (Size) 4.380 (400)
    Ask (Size) 4.440 (200)
    Prev. Close 4.430
    Today's Range 4.400 - 4.460
    52wk Range 1.100 - 10.08
    Shares Outstanding 25,938,064
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill

    Performance

    YTD
    -33.5%
    -33.5%
    1 Month
    -23.9%
    -23.9%
    3 Month
    -28.6%
    -28.6%
    6 Month
    +11.1%
    +11.1%
    1 Year
    +125.6%
    +125.6%

    More News

    Read More
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    Via Chartmill
    IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗
    Via Stocktwits
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
    Via Benzinga
    Why Immuneering Stock Soared Over 40% After-Hours Today ↗
    Via Stocktwits
    News headline image
    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    Immuneering (IMRX) Q3 2025 Earnings Transcript ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    A Preview Of Immuneering's Earnings ↗
    Via Benzinga
    News headline image
    Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data
    Via MarketMinute
    News headline image
    Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
    From Immuneering Corporation
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Top movers in Wednesday's after hours session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Immuneering Corporation - Class A Common Stock publicly traded?
    Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
    What exchange does Immuneering Corporation - Class A Common Stock trade on?
    Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
    The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
    What is the current price of Immuneering Corporation - Class A Common Stock?
    The current price of Immuneering Corporation - Class A Common Stock is 4.400
    When was Immuneering Corporation - Class A Common Stock last traded?
    The last trade of Immuneering Corporation - Class A Common Stock was at 01/15/26 09:31 AM ET
    What is the market capitalization of Immuneering Corporation - Class A Common Stock?
    The market capitalization of Immuneering Corporation - Class A Common Stock is 114.13M
    How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
    Immuneering Corporation - Class A Common Stock has 114M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.